Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Key Terms

precision medicine medical

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

pediatric acute myeloid leukemia medical

A fast-growing blood cancer in children that starts in the bone marrow and interrupts normal production of healthy blood cells; think of the marrow as a factory that begins making only faulty products instead of the variety the body needs. It matters to investors because the disease’s severity and limited treatment options drive demand for new drugs, affect clinical trial urgency, regulatory attention, potential pricing, hospital costs and the commercial prospects of therapies aimed at rare but high-need pediatric cancers.

real-world registry technical

A real-world registry is a systematic database that collects information about patients, treatments, and outcomes as they occur in everyday clinical practice rather than in controlled clinical trials. Investors pay attention because registries reveal how a therapy or medical device performs in routine use—highlighting safety signals, real effectiveness, adoption rates and market demand—much like a continuous customer feedback log that helps forecast sales, risk and long-term value.

longitudinal technical

Longitudinal describes observations or data collected from the same subjects or entities repeatedly over time, tracking how things change rather than a single snapshot. For investors it matters because longitudinal information reveals trends, persistence, and potential cause-and-effect (for example in sales, safety outcomes, or earnings), helping distinguish short-term noise from meaningful long-term shifts—like watching a plant grow rather than looking at a single photo.

patient-reported outcomes medical

Reports provided directly by patients about their symptoms, daily functioning, and quality of life—collected through surveys, apps, or interviews—reflecting how a treatment affects real people rather than lab measures. Investors care because these firsthand accounts help regulators, doctors and payers judge a product’s real-world value and can influence approval, pricing, adoption and long-term sales; think of them as customer reviews that show whether a medical product truly improves everyday life.

multimodal technical

Multimodal describes an approach, product, or system that uses two or more different types of inputs, methods, or channels — for example combining text, images and audio in a technology product, or blending drugs, devices and therapy in medical care. For investors, multimodal solutions can broaden market reach and competitive differentiation but also add development cost, operational complexity and regulatory hurdles; think of it like a hybrid car that offers more capabilities but requires more parts and oversight.

external control arms medical

External control arms are comparison groups assembled from existing patient information—such as medical records, insurance claims, or past studies—used instead of enrolling new patients into the control group of a clinical trial. Investors care because using these outside comparisons can speed development and cut costs, but they introduce uncertainty about how well the groups match, which affects the odds of regulatory approval and the investment’s risk. It’s like judging a new product by past customer reviews rather than running a fresh blind trial.

Master Clinical Trial medical

A master clinical trial is a single, flexible study framework that tests multiple treatments, patient groups, or diseases under one unified plan instead of running many separate trials. Like using one playbook for several games, it saves time and resources, lets researchers compare options more directly, and can speed a successful therapy to market — all outcomes investors watch because they affect development cost, timelines, and commercial risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.

Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.

The collaboration will leverage olivia, Tempus’ AI-enabled personal health concierge app that centralizes health data into a single platform and uses AI to make that information accessible, actionable, and meaningful. Patients participating will receive access to olivia, which will provide tailored materials that utilize Blood Cancer United’s library of educational and patient support and access resources. Materials will be aligned to their disease subtype, treatment stage, and care needs - delivering timely, relevant information throughout their journey. olivia will also enable the collection of longitudinal electronic patient-reported outcomes and questionnaire data to inform and strengthen the registry.

olivia will be used alongside Lens, Tempus’ cloud-based analytics workspace that enables researchers to access and analyze multimodal, de-identified data. This approach will support the creation of one of the largest pAML registries to date, generating insights to drive new therapies and research breakthroughs.

The Blood Cancer United Dare to Dream Project is dedicated to transforming treatment and care for children with blood cancer. By funding groundbreaking research and clinical trial innovation—including PedAL, the first-ever pediatric acute leukemia Master Clinical Trial—the project actively shifts the landscape of pediatric oncology. Beyond the lab, Dare to Dream expands vital support services and leads advocacy efforts to ensure all children with blood cancers have access to affordable, quality healthcare.

“This collaboration will help patients and families now and lays the groundwork for an innovative, patient‑centered approach for the future. For rare disease subtypes like pediatric leukemia, it can be a challenge to enroll enough patients for both an experimental arm and a traditional control arm, which can delay or even prevent trials from starting,” says Gwen Nichols, M.D., Chief Medical Officer, Blood Cancer United. “Our vision is to combine patient‑reported outcomes with de‑identified medical and genomic data to create external control arms and other real‑world comparators, which will allow trials to run faster, let more children receive investigational therapies, and bring safer, more effective treatments to kids sooner.”

“Our work with the Blood Cancer United Dare to Dream Project is a significant step forward in our shared commitment to advance precision medicine, particularly in rare cancers like pediatric AML where high-quality, comprehensive data is desperately needed,” said Max Banaszak, COO of Data & Apps at Tempus. “By combining Tempus’ AI-enabled platform with Blood Cancer United’s deep connection to the patient community, we can create a powerful resource that we hope will improve both care and outcomes for children diagnosed with this devastating disease and accelerate research."

About Blood Cancer United®

Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization’s mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives.

Since the organization’s founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.

Blood Cancer United offers free, trustworthy resources, personalized support, and community for anyone affected by blood cancer. The organization has invested more than $2 billion in research, which continues to increase survival rates. Blood Cancer United advocates nationally and locally for more accessible and affordable healthcare for all patients.

For support and to learn more, visit www.BloodCancerUnited.org. Patients can contact blood cancer information specialists at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. Connect with the organization on Facebook, X, Instagram, LinkedIn and TikTok.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260317693663/en/

Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.